TrialDrugs2020

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.

Mala Dharmalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.